Key facts
- It has raised $15.7M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Shanghai Zhangjiang Science & Technology Venture Capital, Hankang Capital, Apricot Capital (Shanghai), Kangcheng Capital, Shanghai Genesis International Equity Investment Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vison Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Vison Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vison Pharma
Developer of small-molecule drugs intended to treat the hepatitis B virus(HBV) and tumours. The company has self-developed technology around immune regulation, tumor resistance mutations, and functional cure of chronic hepatitis B, SBDD, anda molecular building blocks drug discovery platform, providing patients and hospitals with alternative small-molecule drugs to treat HBV and tumours effectively.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 15
- Ownership
- Privately Held (backing)
Vison Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vison Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vison Pharma in its N-PORT filings yet. We sweep new filings monthly.